Welcome to our dedicated page for Beneficient-A news (Ticker: BENF), a resource for investors and traders seeking the latest updates and insights on Beneficient-A stock.
Beneficient (Nasdaq: BENF) regularly issues news and updates as a technology-enabled platform focused on liquidity, primary capital solutions, and related trust and custody services for holders of alternative assets. Company announcements frequently emphasize its mission to democratize the global alternative asset investment market for mid-to-high net worth individuals, small-to-midsized institutions, and general partners seeking exit options and anchor commitments for their funds.
News about Beneficient often covers earnings and financial results, including quarterly updates on its Ben Liquidity and Ben Custody segments, loan portfolio performance, operating expenses, and capital and liquidity position. These releases describe how the company’s ExAlt loan portfolio is collateralized by a diversified set of alternative assets and how its OptimumAlt technologies guide its balance sheet strategy.
Investors following BENF can also expect corporate governance and regulatory updates, such as changes in board leadership, reverse stock split decisions, and detailed disclosures about the company’s efforts to comply with Nasdaq listing requirements, including bid price, periodic filing, and market value of listed securities criteria. The company has reported regaining compliance with several of these requirements over time.
Another recurring theme in Beneficient’s news is its TEFFI-related activity in Kansas, where its Kansas-chartered fiduciary financial institution contributes to the Kansas TEFFI Economic Growth Trust. Press releases describe how proceeds from TEFFI-financed assets help fund SEED grants that support rural economic development projects in small Kansas communities.
By reviewing Beneficient news on this page, readers can track developments in its alternative asset financing programs, GP primary capital transactions, regulatory milestones, and community-focused initiatives connected to its TEFFI charter.
Beneficient (Nasdaq: BENF) announced a 1-for-8 reverse stock split of its Class A and Class B common stock, effective so shares will trade on a split-adjusted basis when markets open on December 15, 2025. The reverse split was approved by stockholders on December 1, 2025, and will change the CUSIP to 08178Q507. The action is intended to enable Beneficient to regain compliance with Nasdaq's minimum bid price requirement. Every eight pre-split shares will be combined into one post-split share, authorized shares of Class A and Class B will be proportionally reduced, and outstanding equity awards, warrants and convertible preferred stock will be adjusted with higher exercise or conversion prices.
Registered holders in book-entry form need not act; broker-held positions will be adjusted per each broker's process.
Beneficient (NASDAQ: BENF) announced the passing of Thomas O. Hicks, Chairman of the Board, who died on December 6, 2025 at age 79. Mr. Hicks co-founded Hicks & Haas (1984) and Hicks, Muse, Tate & Furst (1989) and was described as a private equity pioneer with a “buy and build” strategy.
He served on Beneficient’s Board since 2017 and was appointed Chairman in July 2025. The company said its Board and management will honor his legacy and continue executing the Company’s mission. The announcement extends condolences to Mr. Hicks’ family and notes an obituary is available.
Beneficient (NASDAQ: BENF) reported fiscal Q2 2026 results for the quarter ended September 30, 2025, highlighting cost reductions, capital-structure moves and improved Nasdaq compliance. Key metrics: investments at fair value $244.0M, Ben Liquidity loan portfolio net $223.1M (gross loans $581M; allowance $358M), cash $4.9M and total debt $104.0M. Operating expenses declined 38.8% excluding certain non-cash items to $13.4M in Q2. Year-to-date asset sales and redemptions generated $46.4M gross proceeds used for debt paydown and working capital. On October 15, 2025, $52.6M of BCH Preferred A-1 held by leadership was converted into Class A common stock, and on October 29, 2025 Nasdaq compliance was regained.
Summary not available.
Beneficient (NASDAQ: BENF) announced that Nasdaq notified the company on October 29, 2025 that it has regained compliance with two listing standards: (i) the Nasdaq periodic reporting requirement after filing its Form 10-K for fiscal year ended March 31, 2025 and Form 10-Q for quarter ended June 30, 2025, and (ii) the $35 million market value of listed securities requirement as an alternative to the minimum stockholders’ equity test.
The company remains noncompliant with the $1.00 per share bid price requirement and must regain compliance within the extension period granted by the Nasdaq Hearings Panel. If compliance is not achieved, the company plans to seek stockholder approval for a reverse stock split intended to restore the $1.00 bid price for the required 10-consecutive trading day period.
Beneficient (NASDAQ: BENF) announced a Limited Conversion where Chairman Thomas O. Hicks and Interim CEO James G. Silk converted approximately $48.0M and $4.6M of Preferred A-1 units of subsidiary BCH into 92,485,639 and 8,808,649 shares of Class A common stock, respectively.
The conversion follows a Nasdaq notice on October 3, 2025 regarding noncompliance with the minimum stockholders’ equity requirement and is intended to support compliance with the MVLS $35M alternative. The Conversion Shares are subject to a voting and lock-up until October 1, 2028, and Messrs. Hicks and Silk agreed to forfeit any appreciation in value of the Conversion Shares at lock-up expiration.
Beneficient (NASDAQ: BENF) reported fiscal 2026 first quarter results for the period ended June 30, 2025, highlighting cost reductions, new primary capital transactions and asset dispositions that strengthened liquidity and reporting compliance.
Key facts: Investments at fair value $263.8M (down from $291.4M); operating expenses $80.0M including a $62.8M loss contingency accrual; operating expenses excluding special items were $17.2M (1% decline YoY); loan portfolio net $230.7M with allowance for credit losses $352.7M; cash $7.6M and total debt $108.4M; asset sales generated $38.1M gross proceeds.
Beneficient (NASDAQ: BENF) reported its Q4 and fiscal year 2025 results, marking significant operational improvements. The company's investments fair value stood at $291.4 million, supporting a net loan portfolio of $244.1 million as of March 31, 2025.
Key highlights include: 91% reduction in operating expenses to $14.3 million in Q4 FY2025, completion of three additional Primary Capital transactions worth $11.8 million, and post-period sale of Customer ExAlt Trust investments for over $36 million. The company appointed Thomas O. Hicks as Chairman and James G. Silk as interim CEO.
Ben's loan portfolio is diversified across 210 private market funds and approximately 710 investments. The company ended the period with $1.3 million in cash and $117.9 million in debt, while receiving $30.4 million in distributions from alternative assets for FY2025.
Beneficient (NASDAQ: BENF) has received a conditional listing extension from the Nasdaq Hearings Panel. The company must meet two key requirements to maintain its listing: file delayed financial reports and demonstrate compliance with the $1.00 per share minimum bid price requirement.
The delayed reports include the Annual Report (Form 10-K) for FY2025 and Q2 2025 Quarterly Report (Form 10-Q). To address the bid price requirement, BENF plans to seek shareholder approval for a reverse stock split if necessary. The company expects to meet these conditions within the granted extension period.
Beneficient (NASDAQ: BENF) has received an additional delisting notice from Nasdaq due to delayed filing of its Q2 2025 Form 10-Q. This follows previous notifications regarding non-compliance with the $1.00 minimum bid price requirement and delayed filing of FY2025 Form 10-K.
The company has requested a hearing before the Nasdaq Hearings Panel to present its compliance plan and seek an extension. While Beneficient is taking steps to address these issues, there is no guarantee the Panel will approve continued listing.